For CY 2026 and subsequent years, we proposed to pay for the stranded and nonstranded not otherwise specified (NOS) codes, HCPCS codes C2698 (Brachytherapy source, stranded, not otherwise specified, per source) and C2699 (Brachytherapy source, non-stranded, not otherwise specified, per source), at a rate equal to the lowest stranded or nonstranded prospective payment rate for such sources, respectively, on a per-source basis (as opposed to, for example, per mCi), which is based on the policy we established in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66785)
Bijwerkingen en risico's 7
Some insurance plansincluding private insurers and certain employer plans may cover Wegovy if you meet eligibility: BMI 30 , or BMI 27 with a weight-related condition (diabetes, high blood pressure, etc.) Medicare and Medicaid generally do NOT cover Wegovy for weight loss, though that could change with evolving policies
Lillys currently approved injection, Zepbound, and Novo Nordisks Wegovy have shown weight loss of roughly 15% to 20% in different trials, according to Reuters, while Lillys oral obesity pill, Foundayo, has delivered about 11% weight loss
Revuforjs approval was supported by data from 104 patients enrolled in the Phase I/II AUGMENT-101 study, in which 21% of treated patients reached complete remission or complete remission with partial hematological recovery
&srotate=0)
